

3-10-04



Patent Application
Attorney Docket No. PC25185A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: COLON-CRUZ, ET AL. :

APPLICATION NO.: 10/689,773

: Examiner: Not Yet Assigned

FILING DATE: OCTOBER 21, 2003

: Group Art Unit: Not Yet Assigned

TITLE: ACYL DERIVATIVES OF 5-(2-(4-(1,2
BENZISOTHIAZOLE-3-YL)-1-
PIPERAZINYL)ETHYL)-6-CHLORO-1,3-
DIHYDRO-2H-INDOL-2-ONE HAVING
NEUROLEPTIC ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Stuart P. Suskind
Agent for Applicant(s)
Reg. No. 40,192

Date: March 9, 2004

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -7122



Patent Application
Attorney Docket No. PC25185A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: COLON-CRUZ, ET AL. :

APPLICATION NO.: 10/689,773 : Examiner: Not Yet Assigned

FILING DATE: OCTOBER 21, 2003 : Group Art Unit: Not Yet Assigned

TITLE: ACYL DERIVATIVES OF 5-(2-(4-(1,2
BENZISOTHIAZOLE-3-YL)-1-
PIPERAZINYL)ETHYL)-6-CHLORO-1,3-
DIHYDRO-2H-INDOL-2-ONE HAVING
NEUROLEPTIC ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Stuart P. Suskind
Agent for Applicant(s)
Reg. No. 40,192

Date: March 9, 2004

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -7122



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25185A	SERIAL NO. 10/689,773
	APPLICANT COLON-CRUZ, ET AL.	
	FILING DATE OCTOBER 21, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	2	0	6	3	6	6	4/27/93	BOWLES	544	284	
		5	3	1	2	9	2	5	5/17/94	ALLEN, ET AL.	544	368	
		5	9	3	5	9	6	0	8/10/9	WALINSKY, ET AL.	514	253	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		0	7	9	0	2	3	6	08/20/97	EPO				
		0	0	1	0	9	7	5	03/02/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.			Hans Bundgaard; Elsevier Science Publishers B.V.; Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities; (1985); p. 1-10.
2.			Davis, et al.; CNS Drugs; Ziprazidone; (1997) vol. 8. No. 2; p. 153-159.
3.			Caley, et al.; The Annals of Pharmacotherapy; Ziprasidone: The Fifth Atypical Antipsychotic; (2002) vol. 36, no. 5; p. 839-851.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.